Johnson & Johnson is facing a new Invokana ketoacidosis lawsuit from a Massachusetts woman alleging permanent injuries.

The woman claims that the manufacturing company failed to warn her and other patients about Invokana complications.

This Invokana ketoacidosis lawsuit is being filed by plaintiff Rose F., who had began using the medication on March 31, 2014. However, not long after the medication was started, Rose reportedly developed ketoacidosis.

Rose had been prescribed Invokana to treat her type-2 diabetes by her physicians who recommended the medication to help reduce her blood sugar.

Invokana is popular in the type-2 diabetes community, as it helps balance blood sugar levels without encouraging weight gain. This drug is a part of the SGLT2 inhibitor medication class which are meant to help type-2 diabetes patients maintain their health when combined with diet and exercise.

Invokana and other SGLT2 inhibitors work by removing excess sugar from the body through urination . Through this treatment mechanism, Rose’s Invokana ketoacidosis lawsuit alleges the medication caused her to develop ketoacidosis.

Overview of Invokana Ketoacidosis

Ketoacidosis is a condition that occurs when the body metabolizes a large amount of fat instead of sugar. This increased fat metabolism causes ketones, or blood acids, to build up in the body and can compound into serious problems. Ketoacisodid can happen due to a deficiency of insulin.

Invokana and other SGLT2 inhibitors have become associated with ketoacidosis after a recent FDA warning and numerous injury reports. On May 15, 2015, the FDA warned that SGLT2 inhibitors like Invokana may increase the risk of ketoacidosis and kidney failure.

This warning came after the FDA’s Adverse Event Reporting System (FAERS), stated that 20 cases of ketoacidosis or ketosis had occurred in patients prescribed SGLT2 inhibitors between March 2013 and June 2014.

Each of these patients required hospitalization or emergency room visits to treat their conditions, with experts suspecting SGLT2 inhibitors may be a contributor.

Even though ketoacidosis can be potentially fatal to patients, Johnson & Johnson allegedly failed to warn against this potential complication. Many patients like Rose are filing legal action against Johnson & Johnson and other manufacturing companies, alleging negligence and failure to warn.

Rose’s Invokana ketoacidosis lawsuit is being filed in multidistrict litigation (MDL) No. 2750, where it will stand alongside other claims alleging similar injuries. Rose states that she never would have taken Invokana if she had known the risk of diabetic ketoacidosis.

This Invokana Ketoacidosis Lawsuit is Case No. 3:17-cv-02213-BRM-LHG, in the U.S. District Court for the District of New Jersey.